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SUMMARY 
This report describes the preparation, homogeneity, stability and characterisation studies as 
well as the purity evaluation of highly purified HbA1c (IRMM/IFCC-466) from human blood. 
HbA1c is defined as the stable adduct from glucose and the N-terminal amino group of the β-
chain of haemoglobin A0 that is beta-N-(1-deoxyfructos-1-yl) haemoglobin [1]. A description 
of the analytical methods used in each of these studies is included. All relevant data from the 
homogeneity and stability studies as well as those for the characterisation measurements are 
presented. 
The certified value is: 
 
 
Certified value1) 
Amount-of-substance 
fraction 
[mmol/mol] 
Uncertainty2) 
[mmol/mol] 
HbA1c/(HbA1c + HbA0)3) 934 22 
 
1) The certified value was calculated as the average of the results for the amount-of-
substance fraction of HbA0 versus HbA0 plus HbA1c of three accepted datasets and 
converted into amount-of-substance fraction HbA1c (1000 mmol/mol – HbA0 mmol/mol). 
Measurements were carried out using the IFCC reference measurement procedure [2] and 
further confirmed by other methods. The certified value, is traceable to the SI. 
2) The certified uncertainty is the expanded uncertainty estimated in accordance with the 
Guide to the Expression of Uncertainty in Measurement (GUM), ISO, 1995. It is expressed 
with a coverage factor (k = 2), corresponding to a level of confidence of about 95 %. 
3) HbA1c is defined as the beta-N-(1-deoxyfructos-1-yl) haemoglobin. HbA0 is defined as the 
non-glycated haemoglobin.  
 
The impurity consisting of HbA0 in IRMM/IFCC-466 was found to be 66 mmol/mol ± 22 
mmol/mol (expressed as HbA0 per HbA1c plus HbA0). 
The total haemoglobin mass fraction in the material was also determined and the 
corresponding value (26.2 ± 0.9 mg Hb/g of solution) is provided as additional material 
information. 
The intended use of this certified reference material is the calibration of the IFCC reference 
measurement procedure and other analogous methods based on the quantification of the N-
terminal hexapeptide that includes the stable glycation. 
The commutability of the material with routine in vitro diagnostic devices has not been 
assessed. Thus, prior to be used as calibrant for routine in vitro diagnostic devices, the 
commutability of IRMM/IFCC-466 should be investigated by the user. 
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GLOSSARY 
2D-Gel Two-dimensional gel electrophoresis 
ANOVA Analysis of variance 
CEofix Capillary Electrophoresis ofix HbA1c kit Analysis  
CE/UV Capillary electrophoresis with ultraviolet detection 
CyanMetHb Cyanmethaemoglobin 
CRM  Certified Reference Material 
CV Coefficient of variation  
EC-JRC European Commission – Joint Research Centre 
EDTA  Ethylenediaminotetraacetic acid 
ESI/MS Electrospray ionization mass spectrometry 
F Snedecor F 
Fcrit Critical value of Snedecor F 
FSQ Unit Food Safety and Quality Unit of IRMM 
Hb Haemoglobin (total) 
HbA0 Non-glycated haemoglobin 
HbA1c Glycated haemoglobin defined beta-N-(1-deoxyfructos-1-yl) haemoglobin 
HPLC High performance liquid chromatography 
ICSH International Council for Standardisation in Haematology 
IFCC International Federation of Clinical Chemistry and Laboratory Medicine 
INSTAND, e.V. Gesellschaft zur Förderung der Qualitätssicherung in medizinischen 
Laboratorien e.V. 
IRMM  Institute for Reference Materials and Measurements 
k Coverage factor 
ℓ Number of laboratories 
LOD Limit of detection 
MHbA1c Molar mass of HbA1c 
MHbA0 Molar mass of HbA0 
MES  2-Morpholinoethanesulfonic acid 
MetHb  Methaemoglobin 
MSbetween  Mean of squares between groups 
MS  Mean of squares 
MSwithin  Mean of squares within groups 
mR  Relative molecular mass  
n Number of replicates 
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N Number of vials  
ע Degrees of freedom 
p-value Error probability 
RM Reference Material 
RM Unit Reference Materials Unit of IRMM 
RSD Relative standard deviation 
s Standard deviation 
sb  Standard deviation of the slope 
sbb Standard deviation between bottles 
swb Standard deviation within bottles 
SKB Streekziekenhuis Koningin Beatrix 
SS Sum of squares 
θ Temperature (°C) 
t0.05,ע  t of Student test at 95 % of confidence and ע degrees of freedom 
TosohA1 Ion exchange chromatographic system from Bioscience Inc, for HbA1c. 
TosohA2 Ion exchange chromatographic system from Bioscience Inc, for HbA0. 
U Expanded uncertainty 
ubb  Standard uncertainty component from homogeneity study 
u*bb Standard uncertainty of the maximum hidden between bottle heterogeneity 
uchar Standard uncertainty component from batch characterisation 
UCRM  Expanded uncertainty of the certified value expressed with a coverage factor 
k = 2, corresponding to a level of confidence of about 95 % 
ults  Standard uncertainty component from long-term stability study 
usts  Standard uncertainty component from short-term stability study 
USM Università degli Studi di Milano 
UV-vis Ultraviolet-visible  
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1. INTRODUCTION 
Diabetes mellitus is a collection of disorders associated with hyperglycaemia, a chronic 
elevation of the concentration of glucose in the blood, as a result of insulin deficiency, insulin 
resistance or a combination of both. This condition affects more than 5 % of the world’s 
population. The major medical and social problems are the chronic diabetic complications, 
which in the end may lead to blindness, renal failure and/or limb amputations. The risk for 
these complications strongly depends on the long-term glycaemic status of the patients. The 
closer the blood glucose concentrations are maintained within the normal intervals, the lower 
the risk of such complications. At present the diagnostic control for the estimation of this 
long-term glycaemic status is based on the determination of haemoglobin-glucose adducts 
(glycated haemoglobins) in blood, formed by non-enzymatic glycation of haemoglobin. The 
major form, about 80 %, of these glycated haemoglobins is haemoglobin A1c (HbA1c), 
resulting from the condensation of glucose with the N-terminal valine residue of each β-chain 
of haemoglobin and subsequent formation of a stable ketoamine. HbA1c has been defined 
as beta-N(1-deoxy) fructos-1-yl haemoglobin, while HbA0 is the non-glycated form of 
haemoglobin. Formation of glycated haemoglobin is essentially irreversible, and the blood 
level depends on both the life span of the red blood cells and the blood glucose level. The 
important role played by the determination of HbA1c vs HbA0 levels to monitor the evolution 
of patients with diabetes mellitus under treatment implies that the analysis of HbA1c is very 
frequently requested in laboratory medicine. 
Despite the above-mentioned clinical importance of the HbA1c determination as a support in 
clinical diagnosis, it is known that the reliability and comparability of test results from the 
large variety of commercial methods available are unsatisfactory. Inter-laboratory 
comparisons have confirmed that the variation is too high and mainly due to systematic 
differences between methods. For these reasons, it is currently not possible to recommend 
scientifically founded decision limits as guidance for the treatment of diabetic patients. The 
methods are based on a variety of analytical principles such as charge differences (ion 
exchange chromatography in HPLC or mini-columns, electrophoresis), affinity binding of 
glycated haemoglobins (affinity chromatography) or the immunological behaviour of HbA1c 
(immunoassays). 
These stated discrepancies in the HbA1c measurements led IFCC to establish a working 
group having the task to develop a reference system for the international standardisation of 
all HbA1c assays. The use of calibrators had previously demonstrated to decrease the inter-
laboratory and inter-method dispersion of glycated haemoglobin results [2, 3, 4]. Therefore, 
among the priorities of this reference system was the production of certified primary 
reference materials as well as the establishment of a suitable reference method for the 
quantification of HbA1c vs. HbA0. 
The IFCC Working Group on HbA1c Standardization has developed a reference 
measurement procedure. This method quantifies the cleaved N-terminal hexapeptide of the 
β-chain of haemoglobin. The glycated and non-glycated hexapeptides are first separated by 
HPLC and then quantified by mass spectrometry (HPLC-ESI/MS) or by UV detection after a 
second separation step by capillary electrophoresis (HPLC-CE/UV). Both detection systems 
give identical results when calibrated with mixtures of highly purified HbA0 and HbA1c. The 
performance of the reference measurement procedure was validated by a network of 
reference laboratories [5]. 
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IRMM/IFCC-466 is a deep-frozen buffered solution containing HbA1c. It was prepared from 
whole blood obtained from diabetic volunteers and provided by Roche Diagnostic GmbH, 
Department for Biochemical Materials, Penzberg, Germany.  
The major objectives of the project included the processing of the material, the evaluation of 
the purity of the candidate reference material and the subsequent characterisation and 
assessment of homogeneity and stability. IRMM/IFCC-466 is to be used in combination with 
IRMM/IFCC-467 for the calibration of the IFCC reference measurement procedure in the 
interval of clinical interest (0 to 150 mmol/mol for amount-of-substance fraction HbA1c in 
HbA0 plus HbA1c). 
The intended use of this material (IRMM/IFCC-466), along with IRMM/IFCC-467 (HbA0, non-
glycated haemoglobin in deep frozen buffered solution prepared from whole blood), as 
primary calibrants for the reference measurement procedure, required us to test for 
additional impurities not detected by the reference method.  While the IFCC reference 
measurement procedure is highly selective for HbA1c and HbA0 since it specifically 
measures the N-terminal hexamer of the β-chain of haemoglobin ignoring the presence of 
other isoforms, the additional methods employed (Tosoh system, CEofix system, UV/Vis 
spectrometry and 2D gel electrophoresis) involve the evaluation of intact haemoglobin or its 
intact chains. 
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2. PARTICIPANTS 
2.1 Processing and bottling of the certified reference material IRMM/IFCC-466 
Roche Diagnostics GmbH, Department for Biochemical Materials, Penzberg, DE 
2.2 Homogeneity and stability studies 
Streekziekenhuis Koningin Beatrix (SKB), Winterswijk, NL 
2.3 Characterisation measurements 
Streekziekenhuis Koningin Beatrix (SKB), Winterswijk, NL 
Università degli Studi di Milano (USM), Milano, IT 
INSTAND e.V., Düsseldorf, DE 
2.4 Evaluation of additional impurities 
EC-JRC Institute for Reference Materials and Measurements (IRMM), Geel, BE 
Università degli Studi di Milano (USM), Milano, IT 
2.5 Evaluation and uncertainty estimation 
EC-JRC Institute for Reference Materials and Measurements (IRMM), Geel, BE 
 
 9
3. CERTIFICATION PROJECT TIME SCHEDULE 
The timing of the project was as follows: 
• Processing of the material: June 2002 
• Shipment to IRMM: July 2002 
• Characterisation study: April 2004 
• Homogeneity study (evaluated with data from stability studies) 
• Stability studies 
o Short-term: March 2004 – October 2004 
o Long-term 1 year: January 2003 – January 2004 
o Long-term 2 years: January 2003 – January 2005 
• Testing for additional impurities: May 2006 
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4. PREPARATION OF THE MATERIAL 
4.1 Description of the material 
IRMM/IFCC-466 was prepared by Roche Diagnostics GmbH from whole blood obtained from 
diabetic volunteers. 
The purification process for HbA1c was performed by multi-step liquid chromatography [8]. 
HbA0 and HbA1c were separated using cation exchange chromatography (SP Sephadex) 
and each of them further purified by sequential affinity chromatography (Mono S) and cation 
exchange chromatography (SP Sephadex).  
The material consists of a deep frozen buffered solution containing HbA1c.  
4.2 Bottling of samples 
A total number of 100 vials, each containing 8 mg of HbA1c in 0.310 mL buffer solution (50 
mmol/L MES, 10 mmol/L KCN, 2 mmol/L EDTA, pH 6.2), were produced and bottled at 
Roche Diagnostics GmbH in June 2002.   
4.3 Dispatching of samples 
Samples were dispatched to the laboratories performing the characterisation and stability 
studies. All samples were packed in special containers filled with dry ice and were 
dispatched within 24 hours to the laboratories. 
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5. MEASUREMENT PROCEDURES  
Various analytical methods were used for the determinations of total Hb and HbA1c and/or 
HbA0. Quantification of HbA1c and HbA0 was carried out using the IFCC reference 
measurement procedure described in section 5.2 while the total haemoglobin mass fraction 
was determined by the use of the ICSH reference method (cyanmethaemoglobin method 
described in section 5.1). 
The relatively small batch size of IRMM/IFCC-466 produced required a combined design of 
the homogeneity, stability and characterisation studies. 
5.1 Method used for stability and homogeneity studies  
The mass fraction of total haemoglobin in solution was determined according to the 
recommended ICSH reference method [6]. Total haemoglobin mass fraction is measured at 
546 nm in the form of cyanmethaemoglobin. This is formed from the reaction between the 
Drabkin’s reagent and the haemoglobin previously oxidised to methaemoglobin.  
This approach was selected for the stability study based on the following assumptions: a) 
equal degradation of both HbA1c and HbA0 since they differ just in the glycation state and, 
b) equal degradation of total Hb and N-terminal hexapeptides of HbA0 and HbA1c, since the 
total amount of Hb in IRMM/IFCC-466 is considered to be comprised of HbA1c and a small 
amount of HbA0. 
For the evaluation of the homogeneity study, it can be assumed that the same homogeneity 
will be found either for the whole molecule or for a peptide derived from the whole molecule 
since the material is a solution. 
5.2 Methods used for characterisation 
The characterisation of the material was performed using the IFCC reference measurement 
procedure [5]. After cleavage of haemoglobin into peptides, the N-terminal hexapeptide 
corresponding to the β-chain of haemoglobin is selected as final and unique target for the 
determination of both forms HbA0 and HbA1c, the latter defined as beta-N(1-deoxy) fructos-
1-yl haemoglobin. 
HPLC-ESI/MS and HPLC-CE/UV were used to determine the identity and amount-of-
substance fraction of the isoform of HbA1c forming the glycated N-terminal hexapeptide of 
the β-chain versus HbA1c plus HbA0 and other isoforms forming the glycated or non-
glycated hexapeptide of the β-chain in IRMM/IFCC-466. From now on in this report, the 
amount-of-substance fraction of the HbA1c isoform forming the glycated N-terminal 
hexapeptide of the β-chain versus the sum of the HbA1c isoform forming the glycated N-
terminal hexapeptide of the β-chain and all haemoglobin isoforms including HbA0 forming the 
non-glycated N-terminal hexapeptide of the β-chain will be referred as the amount-of-
substance fraction of HbA1c versus HbA1c plus HbA0. 
The high specificity of the IFCC reference measurement procedure, measuring only the N-
terminal hexapeptide of the β-chain, does not allow detecting the presence of other glycated 
isoforms of haemoglobin, or even the presence of other proteins in the material. These other 
 12
isoforms would interfere with the ICSH reference method when determining the total Hb 
mass fraction before preparing the calibration solutions by mixing IRMM/IFCC-466 with 
IRMM/IFCC-467 and would thus create a bias. In addition, neither the IFCC reference 
measurement procedure nor the ICSH reference method are able to provide information on 
the oxidation state of IRMM/IFCC-466. 
For all reasons described above, it was decided to apply less specific techniques, described 
in section 5.3, to assess the presence of haemoglobin isoforms in IRMM/IFCC-466.  
5.3 Methods used for testing additional impurities 
a) 2D-gel electrophoresis was applied to IRMM/IFCC-466 and to IRMM/IFCC-466 spiked 
with IRMM/IFCC-467 to obtain an amount-of-substance fraction of 50 mmol/mol of HbA1c 
versus HbA1c plus HbA0 to asses the LOD of the method and to exclude the presence of 
HbA0 in the material. 
b) The molecular mass of the α and β chains (in the glycated or non-glycated forms) was 
verified by analysing IRMM/IFCC-466 with two different LC-MS systems: a) reverse 
phase C4 column coupled to ion trap and b) reverse phase cyano-propyl column coupled 
to a triple quadrupole MS detector. 
c) The presence of different haemoglobin isoforms was tested by applying commercially 
available systems: the capillary electrophoresis-based specific test for HbA1c (CEofix) 
and the ion-exchange HPLC-based Tosoh A1c and HPLC Tosoh A2 methods. These 
systems separate whole-tetrameric haemoglobins that are analysed by measuring their 
absorbance at 415 nm (wavelength characteristic of the Soret band of haemoglobin). The 
chromatographic Tosoh HbA1c system is optimised for the pH interval corresponding to 
the isoelectric point of HbA1c, while Tosoh HbA2 is optimised for the pH interval 
corresponding to the isoelectric point of the haemoglobin isoform HbA2 which is similar to 
that of HbA0. Therefore, Tosoh HbA1c shall be better suited for the evaluation of 
IRMM/IFCC-466 than Tosoh HbA2. 
d) Finally, to evaluate whether HbA1c is undergoing oxidative processes, the absorption 
spectra in the interval of 400-750 nm of IRMM/IFCC-466 was compared to that obtained 
from a fresh haemolysate. 
 
 13
6. STABILITY STUDIES 
The stability study started in January 2003 following an isochronous design [7]. The 
reference temperature for this study was –70 °C, at which no degradation of the analytes 
over a long period can be expected. Due to the limited batch size the number of vials 
submitted to the isochronous schemes, both for short- and long-term stability studies, was 
minimised.  
The stability studies were based on the analysis of total Hb mass fraction by the ICSH 
reference method [6] and according to the assumptions described in section 5.1. That 
approach was found acceptable since no degradation of total haemoglobin implies no 
degradation of HbA1c and/or HbA0.  
6.1 Short-term stability study 
One sample was stored in the dark at –70 °C (reference temperature) and two samples were 
stored at –30 °C, one of them for 4 and the other for 8 weeks.  Each sample was analysed in 
triplicate under repeatability conditions using the method described in section 5.1 and the 
average results are presented in Table 1a. 
The resulting data were evaluated by performing a trend analysis for which results are 
illustrated in Table 1b.  
Table 1a – Short-term stability of IRMM/IFCC-466 at –30 °C: Total Hb mass 
fraction expressed in mg/g of solution 
storage time [week] 
mass fraction 
0 4 8 
Total Hb [mg/g] 25.87± 0.061) 25.97 ± 0.061) 25.90 ± 0.101) 
1) average value ± s (N = 1, n = 3) 
 
Table 1b – Test for significance of the slope: slope (b), standard deviation (sb) and b/sb of 
short-term stability study for IRMM/IFCC-466 
short-term stability study  t-test 
θ [°C] b [(mg/g)/week] sb [(mg/g)/week] t = b/sb t0.05,7 
–30 °C 0.0042 0.0084 0.50 2.365 
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The slope of the regression line (b) was tested for significance using the t-test and the data 
are shown in Table 1b. Since the t value obtained is smaller than t critical value (t0.05,7), it is 
possible to conclude that the obtained slope is not significantly different from zero at 95 % 
confidence level.  
Consequently, the samples are stable at –30 °C for at least 8 weeks. IRMM/IFCC-466 should 
be dispatched on dry ice and after reception, the vials should be kept at –70 °C in the dark 
(see section 6.2).  
6.2 Long-term stability study 
The long-term stability study was conducted over a period of 12 months following an 
isochronous design. Two samples were stored at –70 ºC, one for 6 and the other for 12 
months. The reference temperature was about ─160 °C (storage above liquid N2). The 
results obtained are illustrated in Table 2. 
Table 2a – Long-term stability of IRMM/IFCC-466 at –70 ºC: Total Hb mass 
fraction expressed in mg/g of solution 
storage time [month] 
mass fraction 
0 6 12 
Total Hb [mg/g] 25.87 ± 0.061) 25.90 ± 0.011) 25.97 ± 0.121) 
1) average value ± s (N = 1, n = 3) 
 
Table 2b – Test for significance of the slope: slope (b), standard deviation (sb) and b/sb of 
short-term stability study for IRMM/IFCC-466 
short-term stability study t-test 
θ [°C] b [(mg/g)/month] sb [(mg/g)/month] t = b/sb t0.05,7 
–70 °C 0.0083 0.0047 1.76 2.365 
Using a trend analysis (t-test) of the data, the slope was found not to be significantly different 
from zero at a confidence level of 95 %, indicating that the samples are stable at –70 °C for 
at least 12 months. The uncertainty contribution from stability to the total uncertainty budget 
is estimated according to the following expression [7]: 
x
xx
RSDu
i
lts ∑ −= 2)(  
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with xi being the time points for the individual sample (i), x the shelf life and RSD the relative 
standard deviation of the results of the stability study. 
A shelf-life of 49 months was calculated for the material, according to Pauwels et al. [7,8], 
with an expected relative standard uncertainty (ults) of 1 %. This value is included in the 
uncertainty budget. 
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7. HOMOGENEITY STUDY 
Detailed evaluation of the values for total Hb mass fraction in solution (mg/g) from both, 
short-term and long-term stability studies of IRMM/IFCC-466, showed no significant trend of 
the data with time under the conditions tested. Therefore, it is feasible to assess the 
homogeneity of IRMM/IFCC-466 using the data of both the short-term and the long-term 
stability studies. The condition establishing a minimum number of units to be tested was met 
( ,3 N  N = 100). Since no differences were observed for the total haemoglobin mass fraction 
in solution between –30 °C and –70 °C, both sets of data were combined to estimate the 
uncertainty due to heterogeneity. Therefore, six vials analysed (N = 6) in triplicate (n = 3) 
were considered. The uncertainty contribution ubb was estimated using one-way ANOVA and 
the results of the study are given in Table 3. 
The evaluation of the homogeneity study is performed using the ICSH reference method 
under the assumptions described in section 5.1. Therefore, the uncertainty for the 
homogeneity, calculated from the evaluation of the total haemoglobin mass fraction, can be 
included in the uncertainty budget, UCRM. 
A reliable quantification of between unit heterogeneity is not possible due to the small 
number of replicates per unit. When evaluating the homogeneity of the material using 
ANOVA the maximum inhomogeneity that can be hidden by the method repeatability (u*bb) 
was calculated as follows [8] and included in Table 3: 
( )4
*
1
2
−⋅= nNn
MSwithin
bbu  ;            n
MSMS withinbetween
bbs
−=  
Table 3 - ANOVA results for the homogeneity study of IRMM/IFCC-466 
expressed as total Hb mass fraction in mg/g of solution. 
Source of 
variation 
SS ע MS F p-value Fcrit 
Between 
bottle 
0.031 5 0.006 1.12 0.401 3.106 
Within bottle 0.067 12 0.006    
Total 0.098 17     
 
Using the results from the ANOVA (Table 3), the standard deviation between bottles (sbb) 
and the standard uncertainty of the maximum hidden between-bottle heterogeneity (u*bb) 
were calculated according to the above described formulas.  
• sbb= 0.015 
• u*bb= 0.028  
Since u*bb has a bigger value than sbb, u*bb is further taken into consideration as uncertainty 
component for the homogeneity. 
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Taking into account the average value obtained for total haemoglobin mass fraction in 
solution, 25.91 mg/g of solution, the relative standard uncertainty of the maximum hidden 
between-bottles heterogeneity can be calculated (u*bb/average = 0.11 %). 
The measurements showed an acceptable level of inhomogeneity, when compared to the 
stability and characterisation contributions, all becoming part of the uncertainty budget (Table 
6). 
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8. BATCH CHARACTERISATION 
8.1 Evaluation of additional impurities 
The absence of other proteins in IRMM/IFCC-466 was evaluated using 2D-gel 
electrophoresis. No contamination coming from other proteins was observed for the pH 
interval 3 to 10 and the molecular mass interval from 10 to 100 kDa on silver stained gels.  
Only 2D gel spots at molecular masses around 16 kDa, corresponding to the masses of α 
and β chains (glycated or non-glycated), were observed. A parallel experiment performed on 
a sample of IRMM/IFCC-466 (HbA1c) spiked with IRMM/IFCC-467 (HbA0) to a amount-of-
substance fraction of 50 mmol/mol (HbA0/HbA1c+HbA0) showed no additional spots. 
 
Figure 1. 2D-gel corresponding to IRMM/IFCC-466 (left) and IRMM/IFCC-466 (right) spiked 
with IRMM/IFCC-467 to obtain a amount-of-substance fraction of 50 mmol/mol of HbA1c 
versus HbA1c plus HbA0, the pH interval being 3-10 and the relative molecular mass interval 
10-100 kDa. The α-chains are shown in red (continuous line) while the β-chains are shown in 
green (dashed line). The molecular mass of the α and β chains (in the glycated or non-
glycated forms) of IRMM/IFCC-466 was verified by using two different LC-MS methods as 
described in section 5.3.  
The observed molecular masses are 15126 daltons, 15867 daltons and 16029 daltons for the 
haemoglobin α-chain, non-glycated-β-chain and glycated-β-chain, respectively. The obtained 
results are in complete agreement with the theoretical molecular masses for the haemoglobin 
α-chain and β-chain (glycated and/or non-glycated). 
The presence of different haemoglobin isoforms was tested by applying commercially 
available systems based on CE (CEofix) and HPLC (Tosoh) methodology as described in 
section 5.3. All chromatograms corresponding to these assays can be seen in Annex 1 
(Figures I to IV) while the results are summarized in Table 4. 
Table 4 – Characterisation of Hb isoforms in IRMM/IFCC-466 expressed as an area fraction 
(%) of all Hb isoforms absorbing at 415 nm, corresponding to the amount-of-substance 
fraction under the assumption that the molar extinction coefficients of all Hb isoforms are 
equivalent.  
pH 
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Method 1) 
Component 
Tosoh HbA1c Tosoh HbA2 CEofix A1c Analis kit 
HbA1c 94.5 % 95.7 % 96.4 % 
HbA0 1.4 – 2.0 % 1.3 % 1.1 % 
HbX 2.9 – 3.4 % 1.5 % 2.5 % 
1) CV: 1 % for the Tosoh HbA1c system, 3.8 % for the Tosoh HbA2 system and 2.0 % for the CEofix 
A1c analis kit when measuring IRMM/IFCC-466. Values are expressed as peak area percentage. 
 
In all cases, the estimated purity of HbA1c is higher than when using the IFCC reference 
measurement procedure as can be seen in section 8.2. HbX is eluting at the retention time 
corresponding to a labile HbA1c in the Tosoh HbA1c system and near the position of HbF 
(foetal haemoglobin isoform) in the Tosoh HbA2 and CEofix systems.  However, the 
presence of such isoforms is not consistent with the 3-step purification procedure carried out 
for the preparation of IRMM/IFCC-466. The IFCC reference measurement procedure 
measures HbX as the non-glycated N-terminal hexapeptide as also derived from HbA0. 
When the area fraction of HbX is added to the area fraction of HbA0 the data are consistent 
with the results obtained with the IFCC reference measurement procedure and therefore it 
can be concluded that there are no other haemoglobin isoforms present in IRMM/IFCC-466 
that would not be detected by the IFCC reference measurement procedure but with the ICSH 
reference method.  
The peak corresponding to HbA1c is split when eluting from the chromatographic system 
Tosoh HbA1c (Figure I in Annex 1) but not when using the CEofix A1c system (Figure III in 
Annex 1). A plausible explanation for this observation is the existence of multiple oxidation 
stages for HbA1c in IRMM/IFCC-466. These multiple oxidation states are not distinguished 
by the CEofix system because the addition of KCN converts all of them into the uniform 
cyanmethaemoglobin derivatives. This was confirmed by adding KCN or oxidative conditions 
were applied to fresh haemolysate prior to using Tosoh chromatography.  
This is corroborated by the absorption spectra, in the region of 400-750 nm for the group 
haeme, of IRMM/IFCC-466 and fresh haemolysate (Figure IV in Annex 1). The UV/vis 
absorption spectrum of IRMM/IFCC-466 clearly shows some degree of oxidation. 
In summary, there is a good agreement among the values reported by the three 
commercially available systems. Both HbX and HbA0, impurities detected by the 
commercially available systems (CEofix, Tosoh A1c and Tosoh A2), will be detected as 
HbA0 when using the IFCC reference measurement procedure. The sum of the values 
reported for the impurities by the commercially available systems (expressed as the amount-
of-substance fraction for HbA0 or HbX versus the sum of all detected isoforms, i.e. HbA1c, 
HbA0 and HbX) is somewhat lower than when using the IFCC reference measurement 
procedure. Therefore, these values obtained by the commercially available systems provide 
a solid base for the purity statement of the material using the IFCC reference measurement 
procedure since it is a more conservative estimation. 
 20
8.2 Characterisation 
The goal of this study was to evaluate the amount-of-substance fraction of HbA1c versus 
HbA0 plus HbA1c and any isoform forming the glycated N-terminal hexapeptide in  
IRMM/IFCC-466. The batch characterisation was performed by three laboratories according 
to the IFCC reference measurement procedure that used as prescribed, either the HPLC-
ESI/MS or HPLC-CE as detection system [5]. The amount-of-substance fraction of HbA0 in 
IRMM/IFCC-466 was evaluated by a standard addition protocol according to Finke et al. [9]. 
Laboratories 1 and 3 used the HPLC-ESI/MS detection system, while laboratory 2 used the 
HPLC-CE/UV system. Laboratory 1 performed a single measurement in duplicate on the 
pooled content of 5 vials (N = 1; n = 2). Laboratories 2 and 3 performed the digestion step on 
the individual vials. Laboratory 3 performed two measurements (N = 2 vials, 1 digestion 
each) in triplicate (n = 3) and laboratory 2 performed two measurements (N = 2 vials, 1 
digestion each) in duplicate (n = 2). 
All laboratories provided the results as the mass fraction HbA0 versus HbA1c plus HbA0, i.e. 
as mass fraction of HbA0 impurities in IRMM/IFCC-466. The results were converted to the 
amount-of-substance fraction by applying a conversion factor of 0.99 mol/mol (MHbA0 = 66910 
g/mol, MHbA1c = 67234g/mol). Finally, the amount-of-substance fraction of HbA1c can be 
calculated by subtracting the HbA0 amount-of-substance fraction from 1000 mmol/mol. The 
values, obtained according to the following formula, are summarised in Table 5.  
[ ] [ ] [ ][ ] ⎟⎟⎠
⎞
⎜⎜⎝
⎛ ×−=
molgM
molgM
gmgHbAmolmmolcHbA
HbA
cHbA
/
/
/0/10001
0
1  
 
Table 5 – Results for the characterisation study of IRMM/IFCC-466  given as amount-of-
substance fraction of HbA0 and HbA1c, respectively, versus the sum of HbA1c and HbA0.  
 
HbA0 
Amount-of-substance 
fraction [mmol/mol]1,3) 
 number of 
measurements
[n] 
HbA1c 
Amount-of-substance 
fraction [mmol/mol]2,3) 
Lab. 1 (HPLC-ESI/MS) 57.4 ± 1.4 2 942.6 ± 1.4 
Lab. 2 (HPLC-CE/UV) 64.4 ± 0.4 2 935.6 ± 0.4 
Lab. 3 (HPLC-ESI/MS) 76.2 ± 4.4 6 923.8 ± 4.4 
Average 66.0 - 934.0 
1) Values are expressed as the amount-of-substance fraction HbA0 ± s versus HbA1c plus HbA0.  
2) Values corresponding to the amount-of-substance fraction HbA1c ± s versus HbA1c plus HbA0. 
3) The values reported by the laboratories do not overlap because only information on the 
repeatability of the measurements is covered in the uncertainty stated. 
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9. UNCERTAINTY BUDGET AND ASSIGNED VALUE 
The evaluation described hereafter is based on a concept reported by Pauwels et al. [10] and 
in the GUM [11] and uses available data discussed in the previous chapters. 
9.1 Uncertainty evaluation 
All three sets from the characterisation study (see Table 5) were taken into account for the 
calculation of the uncertainty uchar. Due to the low number of data sets, it was decided to 
determine the uncertainty budget for the batch characterisation according to Pauwels et al. 
[10].  
Two uncertainty components were taken into consideration: a) the uncertainty that is 
exclusively laboratory-dependent [ui] and b) the uncertainty component corresponding to the 
standard uncertainty of the average of the laboratory means [uR]. The final equation for uchar 
is 22 Richar uuu += . The components ui and uR can be calculated by using the following 
expressions: 
l
u
u
l
j
j
i
∑
== 1
2
     ;         
3
minmax xxuR
−=   
Since laboratories provided results for the amount-of-substance fraction HbA0 vs HbA1c plus 
HbA0, the uncertainty estimation for the batch characterisation is calculated for HbA0 and 
directly applied in absolute values to HbA1c. 
The residual component, uR, of the uncertainty budget for the characterisation, uchar, was 
calculated applying a rectangular distribution because of the limited number of laboratories 
participating. Consequently, the uncertainty budget for the characterisation is shown in Table 
6.  
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Table 6 – Uncertainty estimation for the batch characterisation 
of IRMM/IFCC-466 
 CV [%] (for 
HbA0) 
u [mmol/mol] 
Lab 1 2.4 1.381) 
Lab 2 0.6 0.391) 
Lab 3 5.8 4.421) 
ui - 1.55 
UR - 5.43 
uchar2) - 5.64  
1) u is calculated as s  
2) 22 Richar uuu +=  
 
The standard uncertainty for the characterisation (uchar) is found to be 5.64 mmol/mol 
(expressed as mmol HbA1c per mol HbA1c plus HbA0). 
9.1.1 Combined uncertainty 
Based on the findings obtained in the stability and homogeneity studies as well as on the 
scattering of results in the interlaboratory batch characterisation, estimates for ubb 
(homogeneity), ults (long-term stability) and uchar (batch characterisation) were combined  and 
expanded according to the following equation: 
222*2 charltsbbCRM uuuU ++⋅=  
While the estimates for u*bb and ults were based on measurements made with the ICSH 
reference method evaluating the total haemoglobin mass fraction in solution, the calculations 
for uchar were performed using the IFCC reference measurement procedure evaluating just 
the N-terminal hexapeptide of the β-chain of the haemoglobin molecule. However, by taking 
the reasoning given in sections 6 and 7 into consideration, one can estimate the UCRM just as 
described in the above equation. 
9.1.2 Uncertainty budget 
Based on the uncertainty contributions mentioned in sections 6.2, 7 and 9.1 the following 
uncertainty budget was established (Table 7):  
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Table 7 - Uncertainty budget for the 
certified value of IRMM/IFCC-466 
expressed as mmol HbA1c per mol 
HbA1c plus HbA0. 
uncertainties [mmol/mol] 
u*bb1) 1.03 
ults1) 9.34 
uchar 5.64 
UCRM (k = 2) 21.92 
1) calculated from the values obtained for 
total Hb mass fraction in solution. 
 
The relative standard uncertainty of the maximum hidden between-bottles heterogeneity 
calculated using ANOVA, as described in section 6.2, is u*bb/average = 0.11 %. Therefore, 
the value for ubb expressed in mmol/mol and included in the uncertainty budget is 
1.03 mmol/mol. 
As described in section 6.2, the expected relative standard uncertainty for the long-term 
stability (ults) was set to be 1 %. Therefore, the value expressed in mmol/mol included in the 
uncertainty budget is 9.34 mmol/mol. 
9.2 Certified value 
The amount-of-substance fraction certified in IRMM/IFCC-466 is 934 ± 22 mmol/mol 
(expressed as mmol HbA1c per mol HbA1c plus HbA0).  
9.3 Indicative value: total Hb mass fraction 
The mass fraction of total Hb in solution for IRMM/IFCC-466 (glycated haemoglobin, HbA1c) 
was determined by using the ICSH reference method [6]. The colorimetric method was 
applied by two different laboratories. Laboratory 2 analysed five samples, those 
corresponding to the characterisation study and laboratory 1 analysed the samples 
corresponding to the stability study1.  Therefore, the values from the stability studies were 
taken together with those of laboratory 2 for the evaluation of both the total haemoglobin 
mass fraction and its related uncertainty budget.  
 
                                                 
1 The relatively large amount required for the HPLC-ESI/MS measurement did not allow the additional evaluation 
of the total Hb content on those samples. 
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Table 8a – Measurement of the total Hb mass fraction in solution for 
IRMM/IFCC-466 by using the ICSH reference method. 
 total Hb [mg/g]1) n 
Lab. 1 (STS + LTS) 25.91 ± 0.08 6 
Lab. 2 (characterisation) 26.4 ± 0.55 5 
Average (2 labs) 26.16  
1) Values are expressed as mass fraction of total Hb in solution ± s.  
 
The uncertainty was estimated following the approach described in section 9.1. As before, 
two uncertainty components were taken into consideration: a) the uncertainty that is 
exclusively laboratory-dependent [ui] and b) the uncertainty component corresponding to the 
standard uncertainty of the average of the laboratory means (uR). The results are shown in 
Table 8b. 
Table 8b – Uncertainty associated to the total Hb mass 
fraction in solution estimated according to Pauwels et al. [9]  
 u [mg/g] 
Lab 1 0.051) 
Lab 2 0.551) 
ui 0.28 
uR 0.14 
uchar2) 0.31 
1) u is calculated as the s 
2) 22 Richar uuu +=  
 
The residual component, uR of the uncertainty budget for the characterisation, uchar, was 
estimated applying a rectangular distribution because of the limited number of laboratories 
participating (Table 8b). The uncertainty budget for the total haemoglobin mass fraction 
obtained according to section 9.3 is shown in Table 9. The uncertainty contributions for 
stability and homogeneity are those already described for the certified value since the 
method applied for those studies was the Drabkin's method. However, the value 
corresponding to uchar differs since both methods and analytes (first the N-terminal 
hexapeptide and now the total haemoglobin) are different.  
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Table 9 - Uncertainty budget for the total haemoglobin 
mass fraction in solution according to the ICSH method 
in IRMM/IFCC-466 
Uncertainties 
total Hb in solution in 
IRMM/IFCC-466 
[mg/g] 
u*bb 0. 03 
ults 0.26 
uchar 0.31 
UCRM (k = 2) 0.81 
 
The standard uncertainty of the maximum hidden between-bottles heterogeneity calculated 
using ANOVA, as described in section 7, is u*bb = 0.03 mg/g.  
As described in section 6.2, the expected relative standard uncertainty for the long-term 
stability (ults) was set to be 1 %. Therefore, the value expressed in mg/g included in the 
uncertainty budget is 0.26 mg/g. 
The total haemoglobin mass fraction in solution calculated using the ICSH reference method 
and estimated to be 26.2 ± 0.9 mg Hb/g solution. The calculated shelf life, as described in 
section 6.2, is 49 months. 
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10. METROLOGICAL TRACEABILITY 
The certified value, expressed as mmol HbA1c per mol HbA1c plus HbA0, is traceable to the 
SI. The assignment of the certified value was carried out using the IFCC reference 
measurement procedure [5] and further confirmed by other independent methods that tested 
the presence of impurities other than HbA0.  
Initial separation of haemoglobin was accomplished using SP Sephadex. The identity of 
HbA1c and HbA0 was confirmed by the elution time on a Mono S HPLC column and the 
corresponding molecular masses were verified by two different LC-MS systems: a) reverse 
phase C4 column coupled to ion trap and b) reverse phase cyano-propyl column coupled to 
a triple quadrupole MS detector. 
The purity of the material was assessed by HPLC-ESI/MS or HPLC/CE/UV applied on the 
digested N-terminal hexapeptide (glycated for HbA1c or non-glycated for HbA0) and 
excluding the presence of other Hb isoforms by using 2D gel electrophoresis, the ion-
exchange HPLC-based Tosoh A1c and HPLC Tosoh A2 systems and the capillary 
electrophoresis-based specific test CEofix Analis.  Finally, to evaluate whether HbA1c is 
undergoing oxidative processes, the absorption spectrum in the interval of 400-750 nm of 
IRMM/IFCC-466 was compared to that obtained from a fresh haemolysate. 
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11. INSTRUCTIONS FOR USE 
11.1 Intended use 
The intended use of this reference material is the calibration of the IFCC reference 
measurement procedure and analogous methods evaluating the stable glycated N-terminal 
hexapeptide of the β-chain of Hb. The material shall be used for the preparation of calibrants 
within the clinical relevant interval (25 – 110 mmol/mol of HbA1c versus HbA0 plus HbA1c).  
Commutability of the material with routine in vitro diagnostic devices has not been assessed 
and if intended to be used as calibrant for routine in vitro diagnostic devices the user would 
have to assess commutability of IRMM/IFCC-466. 
11.2 Transport and storage 
The IRMM/IFCC-466 is supplied as a deep frozen buffer solution (50 mmol/L MES, 10 
mmol/L KCN, 2 mmol/L EDTA at pH 6.2). Shipment will be carried out on dry ice. On receipt, 
the materials should be stored in the dark at -70 °C. 
11.3 Minimum sample intake 
The minimum sample intake is 20 µL. 
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ANNEX 1: ADDITIONAL CHARACTERISATION MEASUREMENTS 
 
 
Evaluation of IRMM/IFCC-466 using Tosoh HPLC set to quantify HbA1c. 
 
 
 
Figure I. Example for a single run chromatogram obtained by Tosoh HPLC (HbA1c 
program). Whole tetrameric haemoglobins are separated and followed at 415 nm. 
Peak "LA1C+" is an unknown Hb adduct eluted at the same retention time as the 
labile form of HbA1c. The peak corresponding to HbA1c is split for IRMM/IFCC-466 
(figure on the left) but not for the fresh haemolysate (figure on the right). 
 
 
HbA1c 
 
 
Evaluation of IRMM/IFCC-466 using Tosoh HPLC set to quantify HbA0. 
 
 
 
 
Figure II. Example for a single run chromatogram obtained by Tosoh HPLC (HbA2 
program). Left) IRMM/IFCC-466, right) fresh haemolysate. Whole tetrameric 
haemoglobins are separated and followed at 415 nm.  
 
 
Evaluation of IRMM/IFCC-466 using CEofix A1c Analis kit 
 
 
 
Figure III. Capillary electrophoresis for IRMM/IFCC-466. Whole tetrameric 
haemoglobins are separated and followed at 415 nm (HbX corresponds to an 
unknown form of Hb). 
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Absorption spectra for IRMM/IFCC-466 and fresh haemolysate showing the region 
(400-800 nm) corresponding to the haeme group. 
 
 
 
 
 
  
 
 
 
Figure IV. Absorption spectra of IRMM/IFCC-466 and fresh haemolysated showing 
the differences in oxidation states. 
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Abstract 
 
This report describes the preparation, homogeneity, stability and certification studies as well as the purity evaluation of 
highly purified HbA1c (IRMM/IFCC-466) from human blood. HbA1c is defined as the stable adduct from glucose and the N-
terminal amino group of the β-chain of haemoglobin A0 that is beta-N-(1-deoxyfructos-1-yl) haemoglobin [1]. A description of 
the analytical methods used in each of these studies is included. All relevant data from the homogeneity and stability studies 
as well as those for the characterisation measurements are presented. 
The certified value is: 
 
 
Certified value1) 
Amount-of-substance fraction 
[mmol/mol] 
Uncertainty2) 
[mmol/mol] 
HbA1c/(HbA1c + HbA0)3) 934 22 
 
1) The certified value was calculated as the average of the results for the amount-of-substance fraction of HbA0 versus HbA0 
plus HbA1c of three accepted datasets and converted into amount-of-substance fraction HbA1c (1000 mmol/mol – HbA0 
mmol/mol). Measurements were carried out using the IFCC reference measurement procedure [2] and further confirmed by 
other methods. The certified value, expressed as mmol HbA1c per mol HbA1c plus HbA0, is traceable to the SI. 
2) The certified uncertainty is the expanded uncertainty estimated in accordance with the Guide to the Expression of 
Uncertainty in Measurement (GUM), ISO, 1995. It is expressed with a coverage factor (k = 2), corresponding to a level of 
confidence of about 95 %. 
3) HbA1c is defined as the beta-N-(1-deoxyfructos-1-yl) haemoglobin. HbA0 is defined as the non-glycated haemoglobin.  
 
The impurity consisting of HbA0 in IRMM/IFCC-466 was found to be 66 mmol/mol ± 22 mmol/mol (expressed as mmol HbA0 
per mol HbA1c plus HbA0). 
The total haemoglobin mass fraction in the material was also determined and the corresponding value (26.2 ± 0.9 mg Hb/g 
of solution) is provided as additional material information. 
The intended use of this certified reference material is the calibration of the IFCC reference measurement procedure and 
other analogous methods based on the quantification of the N-terminal hexapeptide that includes the stable glycation. 
The commutability of the material with routine in vitro diagnostic devices has not been assessed. Thus, prior to be used as 
calibrant for routine in vitro diagnostic devices, the commutability of IRMM/IFCC-466 should be investigated by the user. 
 
 
 
 
 
The mission of the JRC is to provide customer-driven scientific and technical support 
for the conception, development, implementation and monitoring of EU policies. As a 
service of the European Commission, the JRC functions as a reference centre of 
science and technology for the Union. Close to the policy-making process, it serves 
the common interest of the Member States, while being independent of special 
interests, whether private or national. 
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